DaVita HealthCare Partners is a leading provider of kidney care services in the United States, offering a comprehensive range of dialysis and related healthcare services for patients with chronic kidney failure and end-stage renal disease. The company operates a vast network of outpatient dialysis centers and provides integrated care management and support for patients through various healthcare services, including nutritional counseling, social services, and patient education. DaVita is committed to improving patient outcomes and enhancing the quality of life for those affected by kidney disease while working closely with healthcare providers, payers, and communities to address the evolving challenges of kidney care. Read More
What Happened? Shares of dialysis provider DaVita Inc. (NYSE:DVA) fell 7.1% in the afternoon session after Axios reported that the Department of Health and H...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
DaVita, Franklin Resources, and Archer Daniels Midland have each gained more than 30% year to date in 2026, offering investors diversification away from AI-driven stock market gains.
DaVita’s 20.6% return over the past six months has outpaced the S&P 500 by 7%, and its stock price has climbed to $183.98 per share. This performance may hav...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
DaVita’s second quarter results surpassed Wall Street’s revenue and adjusted profit expectations, but the market response was notably negative. Management at...
Dialysis provider DaVita Inc. (NYSE:DVA) announced better-than-expected revenue in Q2 CY2026, with sales up 5.2% year on year to $3.55 billion. Its non-GAAP ...
